RNA: Where innovation meets precision medicine


RNA: where innovation meets precision medicine

RNA editing

Alcediag specializes in RNA editing, a key epigenetic mechanism that uniquely addresses previously unmet diagnostic needs. Leveraging this cutting-edge technology, Alcediag is at the forefront of innovative solutions in the diagnostic landscape.


Epigenetics is defined as the study of mechanisms that modify gene activity and expression without altering the DNA sequence itself. These modifications encompass a wide range of environmental factors, such as nutrition, physical activity, stress, medication, and exposure to pathogens. Unlike genetic changes, epigenetic alterations are dynamic and reversible. Types of epigenetic changes include DNA methylation (the addition of chemical groups to DNA), histone modification, RNA editing, and more.

RNA Editing

A-to-I RNA editing is an epigenetic mechanism that consists in the substitution by deamination of a precise adenosine (A) nucleotide in an inosine (I) nucleotide within RNA sequences. Inosine is subsequently recognized as guanosine (G) by the translation machinery. This process is carried out by a family of enzymes known as Adenosine Deaminases Acting on RNA (ADARs).

Accumulating evidence strongly supports the critical role of RNA editing in various aspects of RNA metabolism, including mRNA stability, nuclear export, localization, and protein recoding. RNA editing serves as an early regulatory system for gene expression and contributes to the diversification of the entire protein repertoire.

RNA editing alterations have been associated with various disorders, including psychiatric and neurological diseases, as well as cancer and autoimmune diseases. For instance, RNA editing is known to modify highly conserved neurotransmitter receptors and synapse-related factors, underscoring its pivotal role in the modulation of neurotransmission.

Alcediag Expertise

Alcediag specializes in harnessing RNA editing as a pioneering force in developing innovative solutions and products. 

Leveraging this expertise, the company uncovers novel blood biomarkers tailored for specific pathologies or therapeutic areas. Alcediag biomarkers are intricately linked to the underlying mechanisms of action and / or the physiopathology of diseases, ensuring their precision and relevance. By aligning with specific molecular processes, these biomarkers stand as bespoke indicators, clinical significance and performance. Alcediag thus develops solutions such as diagnostic tests, companion diagnostics, monitoring or stratification solutions.

Additionally, Alcediag extends its capabilities to crafting tools for advancing the development of new drugs, solidifying its commitment to pushing the boundaries of medical progress. As such the company operates as the case may be with proprietary cells tests and in the context of pre-clinical studies.

For more information, please refer to the “Products a Services” section.

Machine learning and artificial Intelligence

At the forefront of epigenetics and RNA editing, Alcediag seamlessly integrates artificial intelligence and machine learning into its endeavors, transforming biological information into actionable insights. The synergy between cutting-edge technology and biological expertise is the cornerstone of Alcediag’s approach.

In the development of the algorithms, the company places a profound emphasis on not only leveraging the vast reservoirs of biological data but also on incorporating physiopathology and intricate biological mechanisms. This fusion of data science and biological sciences is a testament to the company’s commitment to building algorithms that are not only technologically advanced but also deeply rooted in the understanding of the intricate web of biological processes.

What sets Alcediag apart is the continuous collaboration between data scientist, neuroscientists and biologists. This interdisciplinary partnership ensures that the computational tools are not just relevant but hold meaningful significance in the study of various pathologies. Importantly, our commitment to transparency and safety extends to the operational phase, where algorithms are frozen. This guarantees a secure and transparent environment for patients, physicians, pharmaceutical companies, and other stakeholders, instilling confidence in the reliability of our solutions. By intertwining the brilliance of machine learning with the nuances of biological intricacies, we strive to unravel the mysteries of genetic information, paving the way for groundbreaking advancements in the field of life sciences.